Insights Into EGFR-Mutant NSCLC

Perspectives on genetic testing practices, initial management, and sequencing of therapies in EGFR-mutant NSCLC

Central – March 29, 2022

Faculty Chair

Narjust Duma, MD

Dana-Farber Brigham Cancer Center, Boston, MA, USA

Southeast – May 17, 2022

Faculty Chair

Stephen Liu, MD

Georgetown University, Washington, DC, USA

More Information

  • Virtual series
  • Southern California, Nevada, Utah, Arizona, New Mexico, Colorado

More Information

  • Virtual series
  • Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee, Virginia, West Virginia

Example Report

Start discovering the insights

View Report


  • A moderated roundtable discussion with community oncologists from the Central region of the United States was held virtually on March 29, 2022
  • Disease-state and data presentations were led by Dr Narjust Duma, from Dana-Farber Brigham Cancer Center, in conjunction with content developed by the Aptitude Health clinical team
  • Insights were obtained on the management and current use of treatment options of EGFR-mutant NSCLC among community physicians


  • Data collection was accomplished through use of audience response system questioning and in-depth moderated discussion
  • The group of advisors comprises 11 oncologists from the Central region of the United States

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.